NCT05193071 is a Phase 4 clinical trial of Aspirin 100mg; Clopidogrel 300mg in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region.

Who is sponsoring NCT05193071?

NCT05193071 is sponsored by General Hospital of Shenyang Military Region.

What drugs are being tested in NCT05193071?

Interventions in NCT05193071: Aspirin 100mg; Clopidogrel 300mg.

What condition does NCT05193071 study?

NCT05193071 studies Ischemic Stroke.

Is NCT05193071 still recruiting?

NCT05193071 is currently completed. Last updated 31 October 2024.

Last reviewed 2024-10-31 · How we verify

NCT05193071

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST)

Completed Phase 4 Last updated 31 October 2024

What this trial tests

Phase 4 trial testing Aspirin 100mg; Clopidogrel 300mg in Ischemic Stroke in 1,022 participants. Completed in 25 October 2024.

Timeline

8 July 2022

Primary endpoint
25 October 2024

25 October 2024

Quick facts

Lead sponsor	General Hospital of Shenyang Military Region
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	1,022
Start date	8 July 2022
Primary completion	25 October 2024
Estimated completion	25 October 2024
Sites	2 locations across China

Drugs / interventions tested

Aspirin 100mg; Clopidogrel 300mg — full drug profile →

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

General Hospital of Shenyang Military Region

Who can join

18 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current guideline recommends to give antithrombotic treatment 24 hours after intravenous thrombolysis in acute ischemic stroke. However, early neurological deterioration will occur in some patients due to no antithrombotic treatment, which is closely associated with poor outcome. The current trial aims to investigate the effectiveness and safety of early antithrombotic treatment after intravenous thrombolysis in minor stroke.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Combining Intravenous Thrombolysis and Dual Antiplatelet Treatment in Patients With Minor Ischemic Stroke: A Propensity Matched Analysis of the READAPT Study Cohort.
Ornello R, Foschi M, De Santis F, Romoli M, et al · · 2024 · cited 12× · PMID 39119964 · DOI 10.1161/jaha.124.036275
Incidence, outcomes and risk factors of rebound neurological deterioration after initial improvement following intravenous thrombolysis: a retrospective cohort study.
Hu J, Hong L, Ling Y, Li S, et al · · 2026 · PMID 41972108 · DOI 10.3389/fnagi.2026.1706795
Diabetes Mellitus and Early Antiplatelet Treatment for Minor Stroke Following Intravenous Thrombolysis: Prespecified Secondary Analysis of the EAST Trial.
Cui Y, Liu JL, Jiang CH, Hou XW, et al · · 2026 · PMID 41944218 · DOI 10.1111/dom.70745

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other General Hospital of Shenyang Military Region trials

Trials by the same sponsor.

NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07462546 — Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT07412249 — Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05193071 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by General Hospital of Shenyang Military Region
Last refreshed: 31 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05193071.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing